Gilead buys Tubulis for ADC capability

# Gilead buys Tubulis for antibody-drug conjugate capability Gilead Sciences said on April 7, 2026, that it has agreed to acquire Munich-based Tubulis, a private cancer biotech, in a deal worth up to $5 billion. The structure includes about $3.15 billion paid at closing plus as much as $1.85 billion in milestone payments tied to future development and commercial events. (gilead.com) The target is not just a single drug. Gilead is buying a technology platform for antibody-drug conjugates, a class of cancer medicines built like guided packages: an antibody finds a tumor marker, a chemical linker holds the package together in the bloodstream, and a potent drug payload is released after the medicine reaches cancer cells. (gilead.com) Drugmakers like these medicines because they aim to solve an old chemotherapy problem. Traditional chemotherapy spreads through the body like a flood, while an antibody-drug conjugate tries to deliver a toxic drug more like a package sent to a street address, which can widen the gap between anti-tumor activity and side effects if the targeting and chemistry work as intended. (tubulis.com) That chemistry is where Tubulis built its pitch. The company says its proprietary conjugation, linker, and payload technologies are designed to create highly stable antibody-drug conjugates that can carry a broader range of cancer-killing payloads and stay intact longer before reaching tumors. (tubulis.com) Gilead’s announcement put special emphasis on two Tubulis platform names: Tubutecan and Alco5. In the companies’ earlier December 3, 2024 collaboration, Gilead said those platforms would be used to discover and develop an antibody-drug conjugate against a selected solid-tumor target, giving Gilead a front-row look at Tubulis’ science before deciding to buy the whole company. (gilead.com) The lead asset coming with the acquisition is TUB-040. Gilead said TUB-040 is a sodium-dependent phosphate transport protein 2B, or NaPi2b, directed topoisomerase I inhibitor antibody-drug conjugate that is already in Phase 1b/2 testing for platinum-resistant ovarian cancer and non-small cell lung cancer. (gilead.com) Tubulis also brings a second clinical-stage program, TUB-030. Company materials describe it as a next-generation antibody-drug conjugate in Phase 1 development, giving Gilead not only a nearer-term lead candidate but also another active shot on goal in solid tumors. (tubulis.com) Seen in isolation, the Tubulis deal looks like a straightforward pipeline add. Seen next to Gilead’s other 2026 transactions, it looks more like a buying spree aimed at rebuilding the company’s future around oncology and immune-system platforms. (investors.gilead.com) In February 2026, Gilead announced a deal to acquire Arcellx for an implied equity value of $7.8 billion, centered on anito-cel, a cell therapy for multiple myeloma. In March 2026, it said it would acquire Ouro Medicines to advance a first-in-class T cell engager program for autoimmune diseases. (investors.gilead.com) That pattern matters because Tubulis gives Gilead something different from a single late-stage asset. It adds a reusable antibody-drug conjugate engine, which can in principle be applied across multiple tumor targets, and that is the kind of platform capability large drugmakers increasingly want when they are trying to build a precision-oncology franchise instead of filling one hole in a pipeline. This is an inference based on the company’s stated focus on expanding “ADC capabilities” and adding “next-generation assets and platforms.” (gilead.com) Gilead already had a foothold in antibody-drug conjugates through its 2020 acquisition of Immunomedics, which brought in Trodelvy. Pharmaceutical Technology reported that Trodelvy reached $1.4 billion in global sales in 2025, so Tubulis can be read as a second step: not buying the first commercial proof point, but buying more of the underlying machinery for what comes next. (pharmaceutical-technology.com) There is also a geographic angle. Tubulis is one of the larger European antibody-drug conjugate startups, and it raised €308 million in October 2025 before later saying its Series C total reached €344 million, showing that Gilead is buying a company that had enough capital and investor support to keep developing independently. (tubulis.com) For patients, none of this guarantees a better medicine. Antibody-drug conjugates still fail for familiar biotech reasons, including weak efficacy, unexpected toxicity, or the inability to show that a more precise design actually improves outcomes in larger trials. That risk is why so much of the Tubulis price is contingent on milestones rather than paid entirely upfront. (gilead.com) For Gilead, though, the logic is clear. The company is paying now to own more of the chemistry, more of the clinical pipeline, and more of the optionality in a cancer field where the winners may be the companies that control not just one successful drug, but the platform that can generate the next five. (gilead.com)